Y-mAbs Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview

Y-mAbs Therapeutics

28/02/2025 13:48

Y-mAbs Therapeutics Inc YMAB.OQ YMAB.O is expected to show a rise in quarterly revenue when it reports  results on March 4 for the period ending December 31 2024

The New York City-based  company is expected to report a 16.8% increase in revenue to $27.29 million from $23.36 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Y-mAbs Therapeutics Inc is for a loss of 12 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Y-mAbs Therapeutics Inc is $21.50​, above​ its last closing price of $5.42. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.16
-0.16
-0.16
Met
-1.6
Jun. 30 2024
-0.13
-0.13
-0.21
Missed
-59.8
Mar. 31 2024
-0.14
-0.14
-0.15
Missed
-10.5​
Dec. 31 2023
-0.20
-0.20
-0.02
Beat
90.1
​​Sep. 30 2023
-0.18
-0.19
-0.18
Beat
3.7
Jun. 30 2023
-0.24
-0.24
-0.14
Beat
42.1​
Mar. 31 2023
-0.32
-0.32
-0.15
Beat
52.9
Dec. 31 2022
-0.44
-0.46
0.03
Beat
106.6

This summary was machine generated February 28 at 13:48 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)